TabsDetailsBasic DetailsDate: Wednesday, August 22, 2018Type: PresentationMedical Product: dabigatran, warfarinHealth Outcome(s): acute myocardial infarction (AMI)myocardial infarctionMaterials: Minor Differences, Major Consequences? Lessons Learned from Replication of a Claims-Based Drug Safety AssessmentAdditional InformationInformationHost: 34th International Conference on Pharmacoepidemiology & Therapeutic Risk ManagementRelated Assessment(s): Abstracts of the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic, August 22–26, 2018 | Abstract 365A Protocol for Assessment of Dabigatran and Selected Safety OutcomesOutcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort StudyContributorsAuthor(s): Ting-Ying Jane Huang, Laura Hou, Laura Shockro, Ella Pestine, Michael Nguyen, Judith C. Maro, Rima Izem
